These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35740608)

  • 1. Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer.
    Zhou Z; Song Q; Yang Y; Wang L; Wu Z
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.
    Wang Y; Chen R; Zhang J; Zeng P
    PLoS One; 2024; 19(4):e0299949. PubMed ID: 38635758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
    Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
    Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma.
    Qin Z; Xie B; Qian J; Ma X; Zhang L; Wei J; Wang Z; Fan L; Zhu Z; Qian Z; Yin H; Zhu F; Tan Y
    Front Oncol; 2023; 13():1144269. PubMed ID: 37056349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent prognostic implications of
    Ma C; Luo H; Cao J; Gao C; Fa X; Wang G
    J Cancer; 2020; 11(23):7009-7022. PubMed ID: 33123291
    [No Abstract]   [Full Text] [Related]  

  • 7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential mechanism of RRM2 for promoting Cervical Cancer based on weighted gene co-expression network analysis.
    Wang J; Yi Y; Chen Y; Xiong Y; Zhang W
    Int J Med Sci; 2020; 17(15):2362-2372. PubMed ID: 32922202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 11. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis of the prognostic and immunological role of SNX29: a potential target for survival and immunotherapy.
    Xu C; Li F; Liu Z; Yan C; Xiao J
    BMC Med Genomics; 2023 Feb; 16(1):34. PubMed ID: 36829159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatics analysis revealing prognostic significance of
    Chen WX; Yang LG; Xu LY; Cheng L; Qian Q; Sun L; Zhu YL
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898978
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of RAC3 in bladder cancer predicts adverse clinical outcome and increased tumor immune response.
    Ou-Yang S; Liu JH; Wang QZ
    Int J Clin Exp Pathol; 2020; 13(12):2937-2949. PubMed ID: 33425095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis.
    Deng Y; Hong X; Yu C; Li H; Wang Q; Zhang Y; Wang T; Wang X
    Oncol Lett; 2021 May; 21(5):344. PubMed ID: 33747201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.